Analyst consensus ratings for Atea Pharmaceuticals (NASDAQ: AVIR) generally lean toward a hold or speculative buy recommendation, reflecting optimism surrounding its antiviral clinical pipeline weighed against the cash-burning nature of pre-revenue biopharmaceutical firms. What percentage of your portfolio are you willing to allocate to high-risk clinical-stage biotech stocks?